TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TDOC - US87918A1051 - Common Stock
7.25 USD
+0.04 (+0.55%)
7.22 USD
-0.03 (-0.41%)
Overall TDOC gets a fundamental rating of 3 out of 10. We evaluated TDOC against 35 industry peers in the Health Care Technology industry. TDOC has a bad profitability rating. Also its financial health evaluation is rather negative. TDOC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
TDOC had negative earnings in the past year.
TDOC had a positive operating cash flow in the past year.
In the past 5 years TDOC always reported negative net income.
TDOC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -7.78%, TDOC perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
With a decent Return On Equity value of -16.09%, TDOC is doing good in the industry, outperforming 62.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -16.09% | ||
| ROIC | N/A |
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.81%
ROE(5y)-134.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 69.80%, TDOC is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
TDOC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TDOC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
2. Health
2.1 Basic Checks
TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TDOC has been increased compared to 1 year ago.
The number of shares outstanding for TDOC has been increased compared to 5 years ago.
TDOC has a worse debt/assets ratio than last year.
2.2 Solvency
TDOC has an Altman-Z score of -6.50. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
TDOC has a Altman-Z score of -6.50. This is amonst the worse of the industry: TDOC underperforms 80.00% of its industry peers.
The Debt to FCF ratio of TDOC is 7.10, which is on the high side as it means it would take TDOC, 7.10 years of fcf income to pay off all of its debts.
TDOC has a Debt to FCF ratio (7.10) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.71 indicates that TDOC is somewhat dependend on debt financing.
TDOC's Debt to Equity ratio of 0.71 is on the low side compared to the rest of the industry. TDOC is outperformed by 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 7.1 | ||
| Altman-Z | -6.5 |
ROIC/WACCN/A
WACC7.3%
2.3 Liquidity
TDOC has a Current Ratio of 2.70. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
TDOC's Current ratio of 2.70 is in line compared to the rest of the industry. TDOC outperforms 54.29% of its industry peers.
A Quick Ratio of 2.60 indicates that TDOC has no problem at all paying its short term obligations.
TDOC has a Quick ratio of 2.60. This is comparable to the rest of the industry: TDOC outperforms 54.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.6 |
3. Growth
3.1 Past
The earnings per share for TDOC have decreased strongly by -13.27% in the last year.
Looking at the last year, TDOC shows a decrease in Revenue. The Revenue has decreased by -2.37% in the last year.
Measured over the past years, TDOC shows a very strong growth in Revenue. The Revenue has been growing by 35.95% on average per year.
EPS 1Y (TTM)-13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.37%
Revenue 1Y (TTM)-2.37%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.2%
3.2 Future
TDOC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.70% yearly.
Based on estimates for the next years, TDOC will show a small growth in Revenue. The Revenue will grow by 1.86% on average per year.
EPS Next Y2.62%
EPS Next 2Y17.78%
EPS Next 3Y12.56%
EPS Next 5Y6.7%
Revenue Next Year-1.79%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.42%
Revenue Next 5Y1.86%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TDOC. In the last year negative earnings were reported.
Also next year TDOC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
91.43% of the companies in the same industry are more expensive than TDOC, based on the Enterprise Value to EBITDA ratio.
TDOC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TDOC is cheaper than 91.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.18 | ||
| EV/EBITDA | 8.56 |
4.3 Compensation for Growth
TDOC's earnings are expected to grow with 12.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.78%
EPS Next 3Y12.56%
5. Dividend
5.1 Amount
TDOC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.25
+0.04 (+0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners71.39%
Inst Owner Change-4.02%
Ins Owners0.53%
Ins Owner Change1.99%
Market Cap1.29B
Revenue(TTM)2.53B
Net Income(TTM)-224.00M
Analysts67.88
Price Target9.26 (27.72%)
Short Float %14.66%
Short Ratio3.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.74%
Min EPS beat(2)-3.18%
Max EPS beat(2)28.67%
EPS beat(4)1
Avg EPS beat(4)-10.77%
Min EPS beat(4)-54.19%
Max EPS beat(4)28.67%
EPS beat(8)4
Avg EPS beat(8)3.56%
EPS beat(12)7
Avg EPS beat(12)-763.36%
EPS beat(16)10
Avg EPS beat(16)-740.69%
Revenue beat(2)0
Avg Revenue beat(2)-1.19%
Min Revenue beat(2)-1.88%
Max Revenue beat(2)-0.51%
Revenue beat(4)0
Avg Revenue beat(4)-1.14%
Min Revenue beat(4)-1.88%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.53%
Revenue beat(12)0
Avg Revenue beat(12)-1.49%
Revenue beat(16)0
Avg Revenue beat(16)-1.45%
PT rev (1m)-0.74%
PT rev (3m)0.64%
EPS NQ rev (1m)1.04%
EPS NQ rev (3m)-6.39%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-6.14%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.51 | ||
| P/FCF | 9.18 | ||
| P/OCF | 4.39 | ||
| P/B | 0.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.56 |
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)0.79
FCFY10.89%
OCF(TTM)1.65
OCFY22.79%
SpS14.26
BVpS7.85
TBVpS-1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -16.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.8% | ||
| FCFM | 5.54% |
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.81%
ROE(5y)-134.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
F-Score5
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 7.1 | ||
| Debt/EBITDA | 5.48 | ||
| Cap/Depr | 42.61% | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 161.46% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.7 | ||
| Quick Ratio | 2.6 | ||
| Altman-Z | -6.5 |
F-Score5
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)48.62%
Cap/Depr(5y)42.73%
Cap/Sales(3y)6%
Cap/Sales(5y)4.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.37%
EPS Next Y2.62%
EPS Next 2Y17.78%
EPS Next 3Y12.56%
EPS Next 5Y6.7%
Revenue 1Y (TTM)-2.37%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-2.2%
Revenue Next Year-1.79%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.42%
Revenue Next 5Y1.86%
EBIT growth 1Y9.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year141.77%
EBIT Next 3Y35.36%
EBIT Next 5Y20.45%
FCF growth 1Y25.22%
FCF growth 3Y9.33%
FCF growth 5Y55%
OCF growth 1Y2.63%
OCF growth 3Y14.86%
OCF growth 5Y57.96%
TELADOC HEALTH INC / TDOC FAQ
What is the ChartMill fundamental rating of TELADOC HEALTH INC (TDOC) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TDOC.
What is the valuation status of TELADOC HEALTH INC (TDOC) stock?
ChartMill assigns a valuation rating of 3 / 10 to TELADOC HEALTH INC (TDOC). This can be considered as Overvalued.
Can you provide the profitability details for TELADOC HEALTH INC?
TELADOC HEALTH INC (TDOC) has a profitability rating of 2 / 10.
What is the expected EPS growth for TELADOC HEALTH INC (TDOC) stock?
The Earnings per Share (EPS) of TELADOC HEALTH INC (TDOC) is expected to grow by 2.62% in the next year.